Image

Global Renal Disease Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Upcoming Report
  • Nov 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60
  • Pharmaceutical
  • Upcoming Report
  • Nov 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Renal Disease Market, By Indication (Acute Kidney Injury, Chronic Kidney Disease, End-Stage Renal Disease, Others), Treatment (Corticosteroids, ACE Inhibitors, Diuretics, Immunosuppressive Therapy, Others), Route of Administration (Oral, Parenteral), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.

Renal Disease Market

Renal Disease Market Analysis and Size

The global renal disease market is expected to witness significant growth during the forecast period. As per the reports of the CDC, it is projected that more than 37 million people in the U.S. suffer from CKD, whereas worldwide, more than 500 million people are affected. An increasing number of patients who are suffering from kidney failure and also the introduction of technologically advanced products, such as low-maintenance dialysis equipment and artificial kidney, are the primary factors expected to drive the market.

Data Bridge Market Research analyses a growth rate in the global renal disease market in the forecast period 2022-2029. The expected CAGR of global renal disease market is tend to be around 5.50% in the mentioned forecast period. The market was valued at USD 96.72 billion in 2021, and it would grow up to USD 148.43 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Renal Disease Market Scope and Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2014 - 2019)

Quantitative Units

Revenue in USD Billion, Volumes in Units, Pricing in USD

Segments Covered

Indication (Acute Kidney Injury, Chronic Kidney Disease, End-Stage Renal Disease, Others), Treatment (Corticosteroids, ACE Inhibitors, Diuretics, Immunosuppressive Therapy, Others), Route of Administration (Oral, Parenteral), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

Pfizer Inc (U.S.), AstraZeneca (U.K.), Bristol-Myers Squibb Company (U.S.), AbbVie.Inc (U.S.), Dr. Reddy's Laboratories Ltd (India), Endo International plc (Ireland), Teva Pharmaceutical Industries Ltd (Israel), Sun Pharmaceutical Industries Ltd (India), Mylan N.V. (U.S.), Novartis AG (Switzerland), Lupin (India), Cipla Inc (India), Aurobindo Pharma (India), Fresenius SE & Co. KGaA (Germany), Sanofi (France), Takeda Pharmaceutical Company Limited (Japan), F. Hoffmann-La Roche Ltd (Switzerland), Abbott (U.S.)

Market Opportunities

  • Increased Drug Approvals
  • Increasing Demand for Retail Pharmacies

Market Definition

Renal disorder is a type of chronic condition which is affecting the functions of the kidney over a time. It is caused by numerous factors such as autoimmune disorders, genetic factors, infection in other parts of the body and sclerotic diseases.  

Global Renal Disease Market Dynamics

Drivers

  • Increased Incidence of Kidney Diseases

The rising prevalence of chronic kidney disease worldwide is majorly responsible for boosting the growth of the global renal drugs market. According to the National Kidney Foundation reports, approximately 10% of the global population is affected by chronic kidney disease (CKD). As per WHO facts 2019, about 1.13 billion people worldwide have hypertension. In the year 2014–2016, diabetes and hypertension were responsible for approximately 75% of kidney failure. Thus, it boosts the market growth.

Oral drugs is expected to boost the market growth. The segment is expected to accelerate the global market as most products are available in capsule and tablet form and it is a very feasible route of administration.

Opportunities

  • Increased Technological Advancements

The growing occurrence of renal failure in developing countries has driven the launch of technologically advanced products in the market. For instance, in February 2014, the U.S. FDA approved the first human clinical trials of blood purification technologies for designing Wearable Artificial Kidney 2.0. This innovation is envisioned to obtain satisfactory and effective results from kidney failure patients. Therefore, technological advancement in the treatment of renal diseases such as renal failure is another factor expediting the market growth.

  • Increasing Demand for Hospitals

The presence of a large number of hospitals in the U.S., combined with a well-developed healthcare infrastructure, is another factor contributing to market growth. For instance, as per the American Hospital Association, there were around 6,090 community hospitals, 208 federal government hospitals, and 625 nonfederal psychiatric hospitals in the U.S. Major increase in the number of hospitals and hospital admissions for acute kidney disease is boosting the demand for dialysis as well as transplant, there by boosting the market growth.

 Restraints/Challenges

  • Side Effects of Renal Drugs

The side effects associated with these renal drugs could curb the growth of the global renal drugs market over a forecast period. Effects such as loss of appetite, fever, rashes, can hamper the market growth.

  • High Cost

The huge expenditure associated with these agents hamper the market growth. Treatments that include corticosteroids, ACE inhibitors, diuretics, immunosuppressive therapy impede the growth of the market.

This global renal disease market market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global renal disease market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Renal Disease Market            

The growing cases of COVID-19 directly correlate with the growth of kidney-related diseases. For instance, as per the report published in 2021, titled, "Acute Kidney Injury in COVID-19: 90 Days of the Pandemic in a Brazilian Public Hospital," 4–37% of COVID-19 cases involve the kidneys, and acute kidney diseases have an occurrence of 50% among hospitalized COVID-19 patients. Therefore, it has been found that the COVID-19 virus is having a major impact on the kidney of patients, which in turn, is projected to increase the burden of kidney disorders in the near future and fuel the market growth. Thus, overall, COVID-19 had a major impact on the global renal disease market.

Recent Developments

  • In May 2021, the U.S. FDA approved AstraZeneca’s Farxiga for treating patients suffering from chronic kidney disease (CKD) in patients who are at higher risk of progression with and without type-2 diabetes.
  • In May 2021, JB Chemicals & Pharmaceuticals launched a new dedicated division called “RENOVA,” which will expand its market presence for the treatment of chronic kidney disease.

Global Renal Disease Market Scope

The global renal disease market is segmented on the basis of indication, treatment, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Indication

  • Acute Kidney Injury
  • Chronic Kidney Disease
  • End-Stage Renal Disease
  • Others

Treatment

  • Corticosteroids
  • ACE Inhibitors
  • Diuretics
  • Immunosuppressive Therapy
  • Others

Route of Administration

  • Oral
  • Parenteral

End User

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

Renal Disease Market Regional Analysis/Insights

The global renal disease market is analyzed and market size insights and trends are provided by indication, treatment, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the global renal disease market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Europe has been witnessing a highest growth for global renal disease market throughout the forecasted period due to the high diagnostic rate and presence of key players in this region.

North America dominates the market due to the growing cases of kidney disorder and the presence of advanced medical facilities in order to maximize the treatment effectiveness for patient suffering from glomerular disease.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Renal Disease Market Share Analysis

The global renal disease market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global renal disease market.

Key players operating in the global renal disease market include:

  • Pfizer Inc (U.S.)
  • AstraZeneca (U.K.)
  • Bristol-Myers Squibb Company (U.S.)
  • Allergan,Inc (U.S.)
  • Dr. Reddy's Laboratories Ltd (India)
  • Endo International plc (Ireland)
  • Teva Pharmaceutical Industries Ltd (Israel)
  • Sun Pharmaceutical Industries Ltd (India)
  • Mylan N.V. (U.S.)
  • Novartis AG (Switzerland)
  • Lupin (India)
  • Cipla Inc (India)
  • Aurobindo Pharma (India)
  • Fresenius SE & Co. KGaA (Germany)
  • Sanofi (France)
  • Takeda Pharmaceutical Company Limited (Japan)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Abbott (U.S.)


SKU-
Why Choose Us


Frequently Asked Questions

The Renal Disease Market is projected to grow at a CAGR of 5.50% during the forecast period by 2029.
The future market value of the Renal Disease Market is expected to reach USD 148.43 billion by 2029.
The major players in the Renal Disease Market are Pfizer Inc (U.S.), AstraZeneca (U.K.), Bristol-Myers Squibb Company (U.S.), AbbVie.Inc (U.S.), Dr. Reddy's Laboratories Ltd (India), Endo International plc (Ireland), Teva Pharmaceutical Industries Ltd (Israel), Sun Pharmaceutical Industries Ltd (India), etc.
The countries covered in the Renal Disease Market are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, etc.